The Pierre Fabre-backed antibody therapy developer has closed a series A round featuring new and founding investors.

Pharmaceutical and cosmetics producer Pierre Fabre has acquired a stake in US-based autoimmune and inflammatory drug developer ValenzaBio in connection with a $70m series A round for the latter. Investment and financial services group Fidelity Management & Research, Surveyor Capital, Ikarian Capital, Janus Henderson Investors and Opaleye Management supplied the series A funds while Pierre…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.